Blueprint Medicines Announces PDUFA Date Extension for NDA of Avapritinib for Treatment of FourthLine Gastrointestinal Stromal Tumor

Blueprint Medicines Announces PDUFA Date Extension for NDA of Avapritinib for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

14:54 EST 6 Feb 2020 | Speciality Pharma Journal

CAMBRIDGE, Mass., Feb. 6, 2020 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its New Drug Application (NDA) seeking accelerated approval …

More From BioPortfolio on "Blueprint Medicines Announces PDUFA Date Extension for NDA of Avapritinib for Treatment of Fourth-Line Gastrointestinal Stromal Tumor"